Lyell Wealth Management LP Sells 200 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Lyell Wealth Management LP lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 12.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,431 shares of the medical research company’s stock after selling 200 shares during the period. Lyell Wealth Management LP’s holdings in IQVIA were worth $281,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc grew its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Performance

Shares of IQVIA stock opened at $196.54 on Thursday. The company has a market capitalization of $34.61 billion, a PE ratio of 26.21, a P/E/G ratio of 1.98 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50-day simple moving average of $199.95 and a two-hundred day simple moving average of $217.09. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Leerink Partners restated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Truist Financial restated a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.